Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SynAct Pharma AB ( (SE:SYNACT) ) has provided an update.
SynAct Pharma has appointed long-serving finance executive Malin Wikstrand as interim Chief Financial Officer, effective 19 January 2026, following the departure of former CFO Björn Westberg. Wikstrand, who has been with the company since 2016 and most recently served as Financial Controller, brings extensive experience in listed-company finance and deep familiarity with SynAct’s financial structure and reporting, which management says will secure continuity and stability as the biotech advances its clinical programs. The search for a permanent CFO is under way, and the company emphasized that its overall strategy, priorities and operations remain unchanged, signalling a limited operational disruption from the leadership transition for investors and partners.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK25.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that specializes in resolution therapy for inflammatory conditions via selective activation of the melanocortin system. Its portfolio comprises oral and injectable selective melanocortin agonists designed to promote anti-inflammatory and inflammation-resolving activity, helping patients restore immune balance and address chronic inflammation.
YTD Price Performance: 5.31%
Average Trading Volume: 131,482
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.27B
Learn more about SYNACT stock on TipRanks’ Stock Analysis page.